In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US

ABSTRACT Background: Bisphosphonates as a class have the potential to cause upper gastrointestinal irritation. Although the generic alendronate sodium tablets are bioequivalent to the branded product, a potential concern is that the pharmaceutical attributes of the various generic formulations my af...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2009-02, Vol.25 (2), p.449-452
Main Authors: Dansereau, Richard J., Crail, Debbie J., Perkins, Alan C.
Format: Article
Language:English
Subjects:
Alendronate - chemistry
Drugs, Generic - chemistry
Tablets - chemistry
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583
cites cdi_FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583
container_end_page 452
container_issue 2
container_start_page 449
container_title Current medical research and opinion
container_volume 25
creator Dansereau, Richard J.
Crail, Debbie J.
Perkins, Alan C.
description ABSTRACT Background: Bisphosphonates as a class have the potential to cause upper gastrointestinal irritation. Although the generic alendronate sodium tablets are bioequivalent to the branded product, a potential concern is that the pharmaceutical attributes of the various generic formulations my affect the potential for local irritation and tolerability. Scope: The in vitro disintegration times were determined using the method described in the US Pharmacopeia 30 (USP 30). The disintegration of three generic alendronate sodium tablets 70 mg available in the United States was compared to that of the branded product. Findings: The mean disintegration times of the generic alendronate sodium tablets ranged from 9 to 10 s for the Barr lots to 108 s for the Watson lot. The disintegration time of the branded product (Fosamax®) was 53 s. The three Barr lots and one Teva lot had rapid disintegration times which were similar to the disintegration standards (
doi_str_mv 10.1185/03007990802648903
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66888846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66888846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583</originalsourceid><addsrcrecordid>eNp9kEFr3DAQhUVpabZpf0AvRaeSHpyMJFuWyCksSbsQyCHN2cj2eFdbW9pI8obccs3f7C-Jl13IIZC5DMz75sF7hHxncMqYKs5AAJRagwIuc6VBfCAzlpciy1VZfiSznZ5NQHFEvsS4BmBcaf2ZHDHNNNdKz8h64ejWpuBpa6N1CZfBJOsdjWlsLUbqO_qA-K9_pEt0GGxDTY-uDd6ZhDT61o4DTabuMUV6UsL_p-dh-YuarbH97kqto2mF9O72K_nUmT7it8M-JndXl3_nf7Lrm9-L-cV11oiCpUzWguk87xDbQpZTGsF50WghagZS11wUWDKARkKuOjlpwBXvuKiVaqEplDgmP_e-m-DvR4ypGmxssO-NQz_GSko1TS4nkO3BJvgYA3bVJtjBhMeKQbUruHpT8PTz42A-1gO2rx-HRifgfA9Y1_kwmBWaPq0aE7Ba-zG4Kfk79i8mjYf9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66888846</pqid></control><display><type>article</type><title>In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Dansereau, Richard J. ; Crail, Debbie J. ; Perkins, Alan C.</creator><creatorcontrib>Dansereau, Richard J. ; Crail, Debbie J. ; Perkins, Alan C.</creatorcontrib><description>ABSTRACT Background: Bisphosphonates as a class have the potential to cause upper gastrointestinal irritation. Although the generic alendronate sodium tablets are bioequivalent to the branded product, a potential concern is that the pharmaceutical attributes of the various generic formulations my affect the potential for local irritation and tolerability. Scope: The in vitro disintegration times were determined using the method described in the US Pharmacopeia 30 (USP 30). The disintegration of three generic alendronate sodium tablets 70 mg available in the United States was compared to that of the branded product. Findings: The mean disintegration times of the generic alendronate sodium tablets ranged from 9 to 10 s for the Barr lots to 108 s for the Watson lot. The disintegration time of the branded product (Fosamax®) was 53 s. The three Barr lots and one Teva lot had rapid disintegration times which were similar to the disintegration standards (&lt; 30 s) for orally disintegrating tablets. Since there is no established disintegration time for alendronate sodium tablets there can be no assurance that the generic tablets are equivalent to the branded product in terms of esophageal exposure. However, the in vitro disintegration times have not been correlated with in vivo disintegration performance. Conclusions: Copies of generic alendronate sodium tablets are approved based on the results of single-dose bioavailability studies in healthy subjects and this is not considered adequate to establish similar disintegration characteristics.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007990802648903</identifier><identifier>PMID: 19192989</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Alendronate - chemistry ; Drugs, Generic - chemistry ; Tablets - chemistry ; United States</subject><ispartof>Current medical research and opinion, 2009-02, Vol.25 (2), p.449-452</ispartof><rights>2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583</citedby><cites>FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19192989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dansereau, Richard J.</creatorcontrib><creatorcontrib>Crail, Debbie J.</creatorcontrib><creatorcontrib>Perkins, Alan C.</creatorcontrib><title>In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT Background: Bisphosphonates as a class have the potential to cause upper gastrointestinal irritation. Although the generic alendronate sodium tablets are bioequivalent to the branded product, a potential concern is that the pharmaceutical attributes of the various generic formulations my affect the potential for local irritation and tolerability. Scope: The in vitro disintegration times were determined using the method described in the US Pharmacopeia 30 (USP 30). The disintegration of three generic alendronate sodium tablets 70 mg available in the United States was compared to that of the branded product. Findings: The mean disintegration times of the generic alendronate sodium tablets ranged from 9 to 10 s for the Barr lots to 108 s for the Watson lot. The disintegration time of the branded product (Fosamax®) was 53 s. The three Barr lots and one Teva lot had rapid disintegration times which were similar to the disintegration standards (&lt; 30 s) for orally disintegrating tablets. Since there is no established disintegration time for alendronate sodium tablets there can be no assurance that the generic tablets are equivalent to the branded product in terms of esophageal exposure. However, the in vitro disintegration times have not been correlated with in vivo disintegration performance. Conclusions: Copies of generic alendronate sodium tablets are approved based on the results of single-dose bioavailability studies in healthy subjects and this is not considered adequate to establish similar disintegration characteristics.</description><subject>Alendronate - chemistry</subject><subject>Drugs, Generic - chemistry</subject><subject>Tablets - chemistry</subject><subject>United States</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kEFr3DAQhUVpabZpf0AvRaeSHpyMJFuWyCksSbsQyCHN2cj2eFdbW9pI8obccs3f7C-Jl13IIZC5DMz75sF7hHxncMqYKs5AAJRagwIuc6VBfCAzlpciy1VZfiSznZ5NQHFEvsS4BmBcaf2ZHDHNNNdKz8h64ejWpuBpa6N1CZfBJOsdjWlsLUbqO_qA-K9_pEt0GGxDTY-uDd6ZhDT61o4DTabuMUV6UsL_p-dh-YuarbH97kqto2mF9O72K_nUmT7it8M-JndXl3_nf7Lrm9-L-cV11oiCpUzWguk87xDbQpZTGsF50WghagZS11wUWDKARkKuOjlpwBXvuKiVaqEplDgmP_e-m-DvR4ypGmxssO-NQz_GSko1TS4nkO3BJvgYA3bVJtjBhMeKQbUruHpT8PTz42A-1gO2rx-HRifgfA9Y1_kwmBWaPq0aE7Ba-zG4Kfk79i8mjYf9</recordid><startdate>200902</startdate><enddate>200902</enddate><creator>Dansereau, Richard J.</creator><creator>Crail, Debbie J.</creator><creator>Perkins, Alan C.</creator><general>Informa UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200902</creationdate><title>In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US</title><author>Dansereau, Richard J. ; Crail, Debbie J. ; Perkins, Alan C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alendronate - chemistry</topic><topic>Drugs, Generic - chemistry</topic><topic>Tablets - chemistry</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dansereau, Richard J.</creatorcontrib><creatorcontrib>Crail, Debbie J.</creatorcontrib><creatorcontrib>Perkins, Alan C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dansereau, Richard J.</au><au>Crail, Debbie J.</au><au>Perkins, Alan C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2009-02</date><risdate>2009</risdate><volume>25</volume><issue>2</issue><spage>449</spage><epage>452</epage><pages>449-452</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>ABSTRACT Background: Bisphosphonates as a class have the potential to cause upper gastrointestinal irritation. Although the generic alendronate sodium tablets are bioequivalent to the branded product, a potential concern is that the pharmaceutical attributes of the various generic formulations my affect the potential for local irritation and tolerability. Scope: The in vitro disintegration times were determined using the method described in the US Pharmacopeia 30 (USP 30). The disintegration of three generic alendronate sodium tablets 70 mg available in the United States was compared to that of the branded product. Findings: The mean disintegration times of the generic alendronate sodium tablets ranged from 9 to 10 s for the Barr lots to 108 s for the Watson lot. The disintegration time of the branded product (Fosamax®) was 53 s. The three Barr lots and one Teva lot had rapid disintegration times which were similar to the disintegration standards (&lt; 30 s) for orally disintegrating tablets. Since there is no established disintegration time for alendronate sodium tablets there can be no assurance that the generic tablets are equivalent to the branded product in terms of esophageal exposure. However, the in vitro disintegration times have not been correlated with in vivo disintegration performance. Conclusions: Copies of generic alendronate sodium tablets are approved based on the results of single-dose bioavailability studies in healthy subjects and this is not considered adequate to establish similar disintegration characteristics.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19192989</pmid><doi>10.1185/03007990802648903</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-7995
ispartof Current medical research and opinion, 2009-02, Vol.25 (2), p.449-452
issn 0300-7995
1473-4877
language eng
recordid cdi_proquest_miscellaneous_66888846
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Alendronate - chemistry
Drugs, Generic - chemistry
Tablets - chemistry
United States
title In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A14%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20disintegration%20studies%20of%20weekly%20generic%20alendronate%20sodium%20tablets%20(70%E2%80%89mg)%20available%20in%20the%20US&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Dansereau,%20Richard%20J.&rft.date=2009-02&rft.volume=25&rft.issue=2&rft.spage=449&rft.epage=452&rft.pages=449-452&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1185/03007990802648903&rft_dat=%3Cproquest_cross%3E66888846%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c351t-6b31944feed5674733225c933b1069b235e7100c6048f62250282f23b88d0c583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66888846&rft_id=info:pmid/19192989&rfr_iscdi=true